[Intervention] for [health problem]

Transcription

1 6-Oct-1 1 PICO 9: Bør seponering af antidepressiva forsøges efter 6 måneder eller 1 måneder efter stabilisering af symptombilledet hos børn, unge og voksne med OCD? 1. Angst: End of treatment Study or Subgroup 1..1 Efter 16 uger Geller Mean 1.8 Test for overall effect: Z = 1.6 (P =.1) SSRI Udtrapning Mean Difference SD Total Mean SD Total Weight IV, Fixed, 9% CI % 1.% -1. [-.84,.4] -1. [-.84,.4] Mean Difference IV, Fixed, 9% CI 1.. Efter -6 uger 1.. Efter uger Total (9% CI) 9 Test for overall effect: Z = 1.6 (P =.1) Test for subgroup differences: Not applicable 1.% -1. [-.84,.4] -1-1 Review Manager. 1

2 6-Oct-1 1. Social funktionsevne: Efter udtrapning (indenfor 6 mdr.) Study or Subgroup 1..1 Efter 16 uger Geller Mean -.8 Test for overall effect: Z = 1. (P =.19) SSRI Udtrapning Std. Mean Difference SD Total Mean SD Total Weight IV, Random, 9% CI % 66.1%.19 [-.1,.47].19 [-.1,.47] Std. Mean Difference IV, Random, 9% CI 1.. Efter -6 uger Romano Test for overall effect: Z =.64 (P =.) %.9% -.1 [-.6,.] -.1 [-.6,.] 1.. Efter uger Total (9% CI) 17 1 Heterogeneity: Tau² =.; Chi² = 1.47, df = 1 (P =.); I² = % Test for overall effect: Z =.4 (P =.66) Test for subgroup differences: Chi² = 1.47, df = 1 (P =.), I² =.% 1.%.7 [-.,.9] Review Manager.

3 6-Oct Livskvalitet: Efter udtrapning (indenfor 6 mdr.) Study or Subgroup 1.4. Efter 16 uger SSRI Udtrapning Mean Difference Mean SD Total Mean SD Total Weight IV, Fixed, 9% CI Mean Difference IV, Fixed, 9% CI 1.4. Efter -6 uger Efter uger Koran Test for overall effect: Z =.9 (P <.1) % 1.% 9.8 [4.91, 14.69] 9.8 [4.91, 14.69] Total (9% CI) 16 Test for overall effect: Z =.9 (P <.1) Test for subgroup differences: Not applicable 19 1.% 9.8 [4.91, 14.69] - - Favours udtrapning Favours SSRI Review Manager.

4 6-Oct-1 1. Drop-out Efter udtrapning Study or Subgroup Events Total Events Total Weight IV, Random, 9% CI 1..1 Efter 16 ugers behandling Fineberg 7 Geller %.% 47.% 1 16 Heterogeneity: Tau² =.9; Chi² = 7.9, df = 1 (P =.8); I² = 86% Test for overall effect: Z = 1.7 (P =.8). [.41,.68].84 [.67, 1.6].67 [.4, 1.6] IV, Random, 9% CI ? 1.. Efter -6 ugers behandling GSK-CPMS-17 Hollander Romano % 14.8% 1.1%.% Heterogeneity: Tau² =.; Chi² =.44, df = (P =.8); I² = % Test for overall effect: Z =.87 (P =.1).6 [.6, 1.7].6 [.8,.81].68 [.44, 1.].61 [.47,.78]?? +? + +? +? +? 1.. Efter ugers behandling Koran Test for overall effect: Z =.1 (P =.) % 17.%.8 [.4,.8].8 [.4,.8] Total (9% CI) % Heterogeneity: Tau² =.; Chi² = 8., df = (P =.1); I² = 4% Test for overall effect: Z = 4.9 (P <.1) Test for subgroup differences: Chi² =.1, df = (P =.9), I² = %.64 [.,.76] Symptomscore (CY-BOCS/Y-BOCS: 9) : Efter udtrapning (indenfor 6 mdr.) Study or Subgroup Events Total Events Total IV, Fixed, 9% CI IV, Fixed, 9% CI Review Manager. 4

5 6-Oct Symptomscore (CGI-I: >4/ CGI-S: ): Efter udtrapning (indenfor 6 mdr.) Study or Subgroup Events Total Events Total IV, Fixed, 9% CI IV, Fixed, 9% CI Review Manager.

6 6-Oct Genhenvisninger (~relapse) Efter udtrapningen Study or Subgroup Events Total Events Total Weight IV, Random, 9% CI Efter 16 ugers behandling Fineberg 7 Geller % 7.1% 8.4% 7 14 Heterogeneity: Tau² =.11; Chi² = 4.9, df = 1 (P =.); I² = 8% Test for overall effect: Z = 1.9 (P =.6).46 [.4,.6].79 [.6, 1.1].6 [.6, 1.] IV, Random, 9% CI ? 1.8. Efter -6 ugers benahdling Hollander Romano % 9.8% 16.% 1 19 Heterogeneity: Tau² =.; Chi² =., df = 1 (P =.97); I² = % Test for overall effect: Z = 1.48 (P =.14).6 [.1, 1.7].6 [.7, 1.41].61 [., 1.17] +? +? +? 1.8. Efter ugers behandling Koran Test for overall effect: Z =.6 (P =.) %.6%.6 [.1,.6].6 [.1,.6] Total (9% CI) % Heterogeneity: Tau² =.; Chi² = 4.9, df = 4 (P =.9); I² = 19% Test for overall effect: Z =.7 (P =.) Test for subgroup differences: Chi² =., df = (P = 1.), I² = %.6 [.46,.78] Review Manager. 6

7 6-Oct Drop-out pga. bivirkninger Efter udtrapning Study or Subgroup Events Total Events Total Weight IV, Random, 9% CI Efter 16 ugers behandling Fineberg 7 Geller %.% 4.% 1 14 Heterogeneity: Tau² =.; Chi² =., df = 1 (P =.88); I² = % Test for overall effect: Z =.8 (P =.4).64 [.11,.79].7 [., 1.78].7 [., 1.9] IV, Random, 9% CI ? 1.9. Efter -6 ugers behandling GSK-CPMS-17 Hollander Romano % 8.%.8% 1 Heterogeneity: Tau² =.44; Chi² =.7, df = 1 (P =.); I² = 7% Test for overall effect: Z =.66 (P =.1).1 [.,.47] 1.94 [.18,.49].4 [.4,.4]?? +? + +? +? +? 1.9. Efter ugers behandling Koran Test for overall effect: Z = 1.61 (P =.11) % 6.%.44 [.16, 1.].44 [.16, 1.] Total (9% CI) % 47 Heterogeneity: Tau² =.6; Chi² = 6.6, df = 4 (P =.16); I² = 9% Test for overall effect: Z =.1 (P =.4) Test for subgroup differences: Chi² =.69, df = (P =.71), I² = %.48 [.,.] Review Manager. 7

8 6-Oct Alvorlige bivirkninger Efter udtrapning Study or Subgroup Events Total Events Total Weight IV, Random, 9% CI Efter 16 ugers behandling Fineberg 7 Geller Heterogeneity: Tau² =.4; Chi² = 1., df = 1 (P =.6); I² = % Test for overall effect: Z =.69 (P =.49) 17.6% 41.1% 61.7%.14 [.1,.64] 1. [.1, 7.18]. [.8,.7] IV, Random, 9% CI ? 1.1. Efter -6 ugers behandling GSK-CPMS-17 Hollander Romano Heterogeneity: Tau² =.; Chi² =.1, df = 1 (P =.7); I² = % Test for overall effect: Z = 1.1 (P =.19) 4 76.% 18.1% 8.%.9 [., 117.4].94 [.1, 7.67] 4.8 [.49, 7.6]?? +? + +? +? +? 1.1. Efter ugers behandling Koran Total (9% CI) % Heterogeneity: Tau² =.; Chi² =., df = (P =.); I² = 14% Test for overall effect: Z =. (P =.8) Test for subgroup differences: Chi² =.8, df = 1 (P =.1), I² = 1.9% 1.18 [.8, 4.91] Review Manager. 8